Results 171 to 180 of about 56,600 (264)

Promoting and inhibiting factors for the implementation of evidence-based non-invasive treatment programs for patients with knee- and/or hip-osteoarthritis: a rapid review. [PDF]

BMC Health Serv Res
Bosompem J, Rasche P, Chikhradze N, Jömann B, Vollmar HC, Otte IC, Busse TS.   +6 more
europepmc   +1 more source

Building High Involvement Work Systems in the Digital Era: Employee Experience‐Oriented Digital HRM and Employee Involvement

Human Resource Management, EarlyView.
ABSTRACT Despite the increasing application of digital technology in management practices, its implications for employee involvement and high involvement work systems (HIWSs) remain largely unexplored. Based on an in‐depth qualitative case study of Tencent—one of China's largest information technology companies—this article explores whether and in what
Wei Wei, Xiaolan Fu
wiley   +1 more source

Considering Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) for Weight Loss: Insights from a Pragmatic Mixed-Methods Study of Patient Beliefs and Barriers. [PDF]

Healthcare (Basel)
DePietro R, Bertarelli I, Zink CM, Canfield SM, Smith J, McElroy JA.   +5 more
europepmc   +1 more source

The effect of body mass index change on breast and uterine cancer risk in middle‐ and older‐aged adults

International Journal of Cancer, EarlyView.
What's New? While baseline body mass index (BMI) is known to affect cancer risk, the impact of BMI change over time remains unclear. This large cohort study evaluated the association between longitudinal BMI change and the risk of breast and uterine corpus cancers in Korean women, with stratification by menopausal and smoking status.
Su Youn Nam, Junwoo Jo
wiley   +1 more source

Longitudinal changes in health‐related quality of life after a breast cancer diagnosis in sub‐Saharan Africa: Evidence from the prospective ABC‐DO cohort

International Journal of Cancer, EarlyView.
What's New? Breast cancer is now the most common malignancy among women in sub‐Saharan Africa (SSA). Its impact on survivors’ quality of life and Global Health Status (GHS), however, remains inadequately studied in this setting. Here, using data from the African Breast Cancer‐Disparities in Outcomes (ABC‐DO) study, the authors examined GHS over time in
Shamsudeen Mohammed, Moses Galukande, Allen Naamala, Groesbeck Parham, Leeya Pinder, Angelica Anele, Shadrach Awa Offiah, Annelle Zietsman, Joachim Schüz, Valerie McCormack, Isabel dos‐Santos‐Silva   +10 more
wiley   +1 more source

Economic and Humanistic Burden of Multimorbidity in the United States: A Longitudinal Study of Expenditure and Quality of Life Trajectories, 2019-2022. [PDF]

Int J Environ Res Public Health
Alliu I, Thapa S, Yu L, Shehaj B, Asifat O.   +4 more
europepmc   +1 more source

A cost‐effectiveness analysis of breast cancer treatment in certified versus non‐certified hospitals in Germany

International Journal of Cancer, EarlyView.
What's New? This study is the first to quantify the cost‐effectiveness of breast cancer treatment in German Cancer Society‐certified hospitals using real‐world data from over 140,000 patients. Analysis on certification‐related costs and survival outcomes demonstrates that high‐quality multidisciplinary care at certified hospitals delivers substantial ...
Min‐Wai Lwin, Olaf Schoffer, Christoph Streissnig, Pauline Wimberger, Michael Gerken, Veronika Bierbaum, Christoph Bobeth, Martin Rößler, Patrik Dröge, Thomas Ruhnke, Christian Günster, Kees Kleihues‐van Tol, Theresa Link, Anton Scharl, Elisabeth C. Sturm‐Inwald, Karin Kast, Thomas Papathemelis, Olaf Ortmann, Monika Klinkhammer‐Schalke, Jochen Schmitt, Michael Schlander   +20 more
wiley   +1 more source

Education as an upstream social security intervention: constructing a competency-based talent development framework in health economics. [PDF]

Front Public Health
Luo H, Li A, Hua H.
europepmc   +1 more source

Real‐world progression‐free survival and overall survival in patients with HR+/HER2− advanced breast cancer treated in first‐line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study

International Journal of Cancer, EarlyView.
What's New? The CDK4/6 inhibitor ribociclib in combination with an endocrine‐based therapy has demonstrated significant progression‐free and overall survival benefits in patients with advanced/metastatic HR+/HER2‐ breast cancer in the pivotal MONALEESA trials.
Peter A. Fasching, Cosima Brucker, Thomas Decker, Anne Engel, Thomas Göhler, Christian Jackisch, Jan Janssen, Andreas Köhler, Kerstin Lüdtke‐Heckenkamp, Diana Lüftner, Frederik Marmé, Marion van Mackelenbergh, Beate Rautenberg, Marcus Schmidt, Rudolf Weide, Pauline Wimberger, Elena Kisseleff, Christina Pfister, Claudia Quiering, Christian Roos, Achim Wöckel   +20 more
wiley   +1 more source

Cost-Effectiveness Analysis of Recombinant Tumor Necrosis Factor Receptor: Fc Fusion Protein as First-Line Treatment for Active Rheumatoid Arthritis in China. [PDF]

Healthcare (Basel)
Zhang R, Ma A.
europepmc   +1 more source